Tag Archives: EW

Top 10 Warren Buffett Stocks To Watch Right Now

The Kraft Heinz Co. is a $100 billion market capitalization company that generates more than $26 billion in annual revenue by selling iconic brands like Heinz Ketchup, Velveeta Cheese and Kraft Macaroni. Starting in October, Kraft Heinzs finances will be overseen by a 29-year-old.

The company announced on Friday that David Knopf will be the new chief financial officer of Kraft Heinz. Knopf has been working since 2015 at Kraft Heinz, where his responsibilities included overseeing the Planters Nuts brand and heading global budget and business planning, as well as zero-based budgeting and financial strategic planning as a vice-president.

LinkedIn

David Knopf’s LinkedIn page.

Knopf is also a partner at 3G Capital, the private equity firm backed by billionaires Jorge Paulo Lemann, Carlos Alberto Sicupira, and Marcel Herrmann Telles. 3G partnered with Warren Buffett to buy Heinz in a $23 billion deal and then merged the company with Kraft.

Top 10 Warren Buffett Stocks To Watch Right Now: Westell Technologies, Inc.(WSTL)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested small cap high-performance wireless infrastructure solutions stock Westell Technologies (NASDAQ: WSTL) as a buy for our short-term portfolio:

Top 10 Warren Buffett Stocks To Watch Right Now: The Herzfeld Caribbean Basin Fund, Inc.(CUBA)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    This "Trump pick" is a snub to the President’s trade and diplomatic reversals of Obama’s wins regarding Cuba. We are buying back Herzfeld Caribbean Basin Fund (CUBA), following in the footsteps of its founder, Tom Herzfeld, and his son Erik.

Top 10 Warren Buffett Stocks To Watch Right Now: Statoil ASA(STO)

Advisors’ Opinion:

  • [By Cameron Swinehart]

    Going forward I will be looking to add investments on my watchlist and trim other positions. It will be interesting to see how an overweight commodity portfolio will perform relative to the rest of the market.

     Cost Basis# SharesCurrent Price% of PortfolioCurrent ValueReturnMetal/Miners      Sprott Physical Gold Trust (PHYS)$12.4985$11.043.75%$938.40-13.13%Sprott Physical Silver Trust (PSLV)$7.95125$8.744.37%$1,092.509.04%FreePort-McMoran (FCX)$31.6731$33.874.20%$1,049.976.50%Ishares MSCI Global Gold Miners ETF (RING)$13.0695$10.644.04%$1,010.80-22.74%Energy      Statoil ASA(STO)$21.7940$22.683.63%$907.203.92%Vanguard Natural Resources LLC (VNR)$27.5636$27.874.01%$1,003.321.11%ConocoPhillips (COP)$63.6822.43$71.006.37%$1,592.5310.31%Agriculture      CVR Partner LP (UAN)$26.3630.9$18.932.34%$584.94-39.25%Adecoagro$6.78125$7.443.72%$930.008.87%Archer-Daniels Midland (ADM)$34.8030$37.244.47%$1,117.206.55%Mixed Commodity      Powershares DB Commodity Index (DBC)$26.3540$25.954.15%$1,038.00-1.54%Sprott Resource Corp$3.34400$2.714.34%$1,084.00-23.25%    Total % of portfolio49.40%               Cost Basis12,666.00      Current Value12,348.86      Return-2.50%  Source: Investing For The Future Surge In Commodity Prices

    Disclosure: I am long ADM, FCX, UAN, AGRO, RING, VNR, SCPZF.PK, COP, DBC, PHYS, PSLV. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More…)

  • [By Jayson Derrick]

    BP plc (ADR) (NYSE: BP), Royal Dutch Shell plc (ADR) (NYSE: RDS-A) (NYSE: RDS-B) and Statoil ASA(ADR) (NYSE: STO) are expected to outperform their peers by offering: 1) the greatest rate of change in cost reduction through technology and innovation, 2) upstream portfolios with an attractive risk to reward profile and 3) sufficient liquidity to invest in future growth.

  • [By Ben Levisohn]

    We believe that the equity market has neutralised much of its underweight energy positioning in 4Q/1Q, but was caught by the sharp rally in crude from end-January. Our base-case sees oil prices still higher by end-2016 (we see >$50/bbl), albeit with a choppy 2Q likely ahead. In this scenario a modest, rather than fully-fledged price-recovery we continue to place a lot of importance on self-help in driving ROE expansion (as opposed to relying simply on oil-leverage). Value-adjusted, we like the self-help stories around Total, Chevron, Statoil (STO), Royal Dutch Shell and Eni (E) in the group. Total is on the Citi European Focus list.

  • [By Paul Ausick]

    Norway’s Statoil ASA (NYSE: STO) announced this morning that it has acquired stakes in two North Sea projects from France’s Total S.A. (NYSE: TOT). The transaction, valued at $1.45 billion, includes a 51% equity stake in the Martin Linge field and a 40% stake in the Garantiana discovery, both located on Norway’s continental shelf.

  • [By Todd Shriber, ETF Professor]

    NORW reflects Norway's oil exposure. The ETF allocates nearly 28.8 percent of its weight to the energy, 870 basis points more than it devotes to its second-largest sector exposure, financial services. State-run Statoil ASA(ADR) (NYSE: STO) is NORW's largest individual holding at a weight of 15.3 percent, or 560 basis points more than NORW allocates to its second-largest holding.

  • [By Ben Levisohn]

    Should oil prices recover, we believe that deepwater drilling activity growth should lag growth in US shale activity, as project economics is generally better in US shales, and E&Ps involved in US shales are generally quicker to react. Deepwater activity is largely comprises a handful of companies (Petrobras (PBR), Statoil (STO), Total (TOT), Shell (RDS.A), BP (BP), ONGC, ExxonMobil (XOM) and Chevron (CVX)) and it is unlikely that these companies can meaningfully increase their rig demand in a short period of time to absorb the current oversupply. Thus, should oil prices rise in 2018, rig demand may increase, but likely not enough to tighten the market, given that supply equaling 43% of current working rig count is stacked and new supply equaling 25% of working rig count is under-construction and should be entering the market in the coming years. As a result, while we expect some improvement in rig utilization owing to rig retirements, it will unlikely be strong enough to meaningfully improve rates in 2018 above spot levels. Any demand increase in the interim could slow rig retirements materially, and be self-defeating. We thus are Sell rated on Transocean, Atwood and Noble.

Top 10 Warren Buffett Stocks To Watch Right Now: SandRidge Mississippian Trust II(SDR)

Advisors’ Opinion:

  • [By Paul Ausick]

    Sandridge Mississippian Trust II (NYSE: SDR) dropped about 18% Monday to post a new 52-week low of $0.75 after closing at $0.95 on Friday. The 52-week high is $1.79. Volume was around 1.3 million, more than nine times the daily average of around 160,000. The company had no specific news.

Top 10 Warren Buffett Stocks To Watch Right Now: Ono Pharmaceutical Co., Ltd. (OPHLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.

Top 10 Warren Buffett Stocks To Watch Right Now: Vince Holding Corp.(VNCE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Vince Holding Corp (NYSE: VNCE) were down around 15 percent to $3.67. Vince Holding projects full-year sales and EPS to come in at or below the low end of its earlier issued outlook.

  • [By Peter Graham]

    Small cap upscale apparel brandretailer Vince Holding Corp (NYSE: VNCE) reported Q1 2017 financial results before the market opened this morning. Net sales decreased 14.2% to $58.0 million as wholesale segment sales decreased 20.9% to $35.4 million, primarily due to a reduction in full-price orders as a result of the elimination of the Companys summer delivery, and asdirect-to-consumer segment salesfell 1.0% to $22.6 million. Comparable sales decreased 5.7%, including e-commerce sales, due to a decrease in average order value.

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

  • [By Lisa Levin]

    Shares of Vince Holding Corp (NYSE: VNCE) were down around 41 percent to $0.800. Vince Holding reported a Q4 loss of $162.1 million on revenue of $63.9 million.

Top 10 Warren Buffett Stocks To Watch Right Now: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.

    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.

  • [By Lisa Levin]

    Breaking news

    Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan.
    Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat.
    Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share.
    Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.

Top 10 Warren Buffett Stocks To Watch Right Now: Zumiez Inc.(ZUMZ)

Advisors’ Opinion:

  • [By Chris Lange]

    Zumiez Inc. (NASDAQ: ZUMZ) is set to report its fiscal second-quarter results on Thursday. The consensus estimates predicta net loss of $0.08 per share and $177.35 million in revenue. Shares were changing hands at $16.61 on Fridays close. The consensus price target is $15.20, and the stock has a 52-week range of $11.53 to $23.45.

  • [By Lisa Levin]

    Zumiez Inc. (NASDAQ: ZUMZ) was down, falling around 10 percent to $19.78. Zumiez reported in-line earnings for its third quarter on Thursday.

    Commodities

  • [By Lisa Levin]

    Zumiez Inc. (NASDAQ: ZUMZ) was down, falling around 12 percent to $19.15. Zumiez reported in-line earnings for its third quarter on Thursday.

    Commodities

  • [By Dan Caplinger]

    Friday was a good day on Wall Street, as the stock market responded favorably to encouraging news on the employment front. The U.S. unemployment rate dropped on fairly strong job creation during the month of February, and that helped push the Dow, S&P 500, and Nasdaq Composite to modest gains of roughly between a quarter percent and a half percent. Yet even with a positive mood among market participants, some stocks weren’t able to participate in the end-of-week rally. Finisar (NASDAQ:FNSR), Zumiez (NASDAQ:ZUMZ), and Winnebago Industries (NYSE:WGO) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top 10 Warren Buffett Stocks To Watch Right Now: Arch Coal, Inc. (ARCH)

Advisors’ Opinion:

  • [By Ben Levisohn]

    The VanEck Vectors Coal ETF has gained 1.1% to $12.28 at 2:01 p.m. today, while Arch Coal (ARCH), which resumed listed trading yesterday after emerging from bankruptcy, has fallen 3% to $62.98.

Top 10 Warren Buffett Stocks To Watch Right Now: Daktronics, Inc.(DAKT)

Advisors’ Opinion:

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is projected to report its quarterly earnings at $0.08 per share on revenue of $156.17 million.

    Guidewire Software Inc (NYSE: GWRE) is estimated to post its quarterly earnings at $0.06 per share on revenue of $92.43 million.

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is estimated to report its quarterly earnings at $0.08 per share on revenue of $156.17 million. Daktronics shares slipped 0.13 percent to close at $7.97 on Tuesday.

Best Safest Stocks To Own For 2018

Gasoline futures soared Monday as Tropical Storm Harvey continued to wreak havoc on Texas, knocking major Gulf Coast refineries out of action.

And while the storm is also expected to curtail offshore crude oil production in the Gulf of Mexico, crude futures are under pressure. Thats because the supply impact is more than offset by the hit to demand for crude by the refinery shutdowns.

See: Hurricane Harvey highlights biggest impact of shale-oil revolution

Best Safest Stocks To Own For 2018: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By Lisa Levin]

    Breaking news

    Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan.
    Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat.
    Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share.
    Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.

    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

Best Safest Stocks To Own For 2018: Tucows Inc.(TCX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tucows Inc. (USA) (NASDAQ: TCX) shares shot up 17 percent to $42.45 after the company announced plans to acquire eNom from Rightside for $83.5 million.

  • [By Anders Bylund]

    Shares of Tucows (NASDAQ:TCX) rose 12.1% in March 2017, according to data from S&P Global Market Intelligence.

    So what

    The provider of online business services and a budding bundle of mobile and fiber-optic communications products started March with a bang, announcing a brand-new $40 million share buyback program. For a company with a $476 million market cap at the time, that’s a pretty serious and shareholder-friendly commitment.

Best Safest Stocks To Own For 2018: Black Diamond, Inc.(BDE)

Advisors’ Opinion:

  • [By Jim Robertson]

    At the beginning of the week, our Under the Radar Moversnewsletter suggested small cap sporting & outdoor goods stock Black Diamond Inc (NASDAQ: BDE) as a short/bearish trade:

Best Safest Stocks To Own For 2018: Unilever NV(UN)

Advisors’ Opinion:

  • [By Teresa Rivas]

    Earlier this year, Unilever (UN) recently declined Kraft Heinz (KHC) merger bid. That means that if the company still wants to do a deal, Mondelez International (MDLZ) and PepsiCo (PEP) are the next logical partners, writes Susquehannas Pablo Zuanic.

    Getty Images

    Zuanic upgraded Pepsi from Neutral to Positive today and raised his price target from $118 to $132. He writes that a Pepsi deal would have more strategic merits, hence his upgrade (as he emphasizes that not much has changed in terms of fundamentals for the firm).

    More detail from his note:

    With investors apparently seeing MDLZ as the next likely KHC target, and Coca-Cola (KO) the next Anheuser-Busch (BUD) target, PEP shares have lost visibility and now trade at a 25% discount to KO on apples-to-apples comps. We see value here, on franchise strength, efforts to align the F&B portfolio with consumer health trends, and the growing optionality value of a joint KHC/BUD bid for PEP. We argue that, together, the Kendall Jenner commercial, the Aspartame to-be-or-not-to-be zigzagging, the new, new, new alt low-cal cola (Pepsi Zero sugar), the ongoing underperformance in U.S. CSDs (25% only of the company), the lack of scale in non-CSD NARTDs vs. KO (other than Gatorade), and now talk of PEP buying Brazilian dairy company Vigor S.A. (a JBS subsidiary that would better fit KHC or ULVR), all paint a picture of a company still struggling to set a new direction (with all due respect). In this regard, we think PEP may be more vulnerable than MDLZ to a KHC bid (jointly done with BUD). We also see greater strategic fit for KHC with PEP Food/Snacks (than with MDLZ), and argue that PEP Beverages fits BUD better than KO, as the PEP bottling operations in key regions (including NA) remain in the hands of PEP (KO, on the other hand will be fully refranchised by end of 2017). So we are upgrading PEP to Positive with a $132 price target by December 17. Yes, the Unilever rebuff

  • [By Lisa Levin]

    In trading on Tuesday, industrial shares fell by 0.04 percent. Meanwhile, top losers in the sector included Unilever N.V. (ADR) (NYSE: UN), down 8 percent, and Magal Security Systems Ltd. (USA) (NASDAQ: MAGS), down 6 percent.

Top 10 Medical Stocks To Buy For 2018

We’re one day from the election, and there are a number of marijuana initiatives on state ballots.

That’s why we’re featuring the top marijuana stocks to watch now. You see, this week is poised to be the biggest week of the year for marijuana stocks. In fact, this week could be historic for the legal and medical marijuana industry.

A record nine states have marijuana initiatives on the ballot this year.

Legal use of recreational marijuana is on the ballot in Arizona, California, Maine, Massachusetts, and Nevada. If passed, those five states will join Alaska, Colorado, Oregon, Washington, and the District of Columba, where adults are free to use marijuana recreationally.

Medical marijuana initiatives are on the ballot in Arkansas, Florida, Montana, and North Dakota.

Top 10 Medical Stocks To Buy For 2018: Panasonic Corporation (PCRFY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    A Unilever vs. Panasonic (OTCPK:PCRFY) showdown seems to be something out of an alternative, weird universe. But that’s exactly what has been happening in the Asia-Pacific region, where Unilever is now a major seller of air and water purification devices. The acquisitions of Qinyuan and Pureit water purifiers, as well as the acquisition of Sweden-based Blueair in 2016, reflects Unilever’s latest growth strategy of reducing exposure to low-growth brands in favor of greater investments in higher-growth products with strong social and environmental credentials.

  • [By SEEKINGALPHA.COM]

    SMMYY is a subsidiary of the Sumitomo Group. SMMYY is a major smelter and refiner of copper, nickel and gold in Japan, and has a 27.5% stake in the Ambatovy Nickel Project in Madagascar, along with Sherritt International and Korea Resources Corp. Feedstock for the refinery is nickel cobalt mixed sulphide from its Taganito and Coral Bay mines in the Philippines (noting the Philippines is a risky supply source at this time). Sumitomo supply Panasonic (OTCPK:PCRFY) who supply Tesla (NASDAQ:TSLA); however, this can change. Generally, I like the stock; however, at this time, valuation looks full, trading on a 2017 PE of 32.8, and 2018 PE of 14.8. Good to buy after a pullback if that occurs.

  • [By SEEKINGALPHA.COM]

    Clean Technica reported on September 1 that “Sony is entering the EV battery manufacturing industry”. And “considering that electric vehicle batteries are going to be the main supply bottleneck for the upcoming auto market’s embrace of EVs, the entry of Sony into the field is very notable. Most of the other manufacturers (Panasonic (OTCPK:PCRFY), LG Chem (OTC:LGCLF), etc.) already have more or less all of their production capacity locked up for the coming years – meaning there’s not much left for the auto manufacturers that are running behind, thereby limiting potential EV sales for the firms in question. Sony’s (NYSE:SNE) entry into the field should open things up a bit more”. Certainly a good move by Sony and helpful for the EV companies that will find themselves in need of batteries, and limited availability, should EVs reach 10% by 2020.

  • [By Ben Levisohn]

    During the early stages of a new innovation, interdependent architectures and integrated companies best optimize performance and functionality. This trend has played out in computing and handsets, and we see the same trend playing out in EVs. We find Tesla and BYD1 , by far, the most vertically integrated players in EVs, with huge scale advantages. In addition, LG Chem, Panasonic (PCRFY), Samsung SDI, BYD, and CATL are clear scale leaders in batteries (CATL is not publicly traded. All but Samsung SDI and BYD are not covered by Bernstein.).

Top 10 Medical Stocks To Buy For 2018: Semtech Corporation(SMTC)

Advisors’ Opinion:

  • [By Monica Gerson]

    Semtech Corporation (NASDAQ: SMTC) is projected to post its quarterly earnings at $0.27 per share on revenue of $128.38 million.

    Ollie’s Bargain Outlet Holdings Inc (NASDAQ: OLLI) is estimated to post its quarterly earnings at $0.17 per share on revenue of $190.44 million.

Top 10 Medical Stocks To Buy For 2018: Hostess Brands, Inc. (TWNK)

Advisors’ Opinion:

  • [By Paul Ausick]

    There was an IPO of sorts last week when Gores Holdings II raised $375 million with an offer of 37.5 million units at $10 per unit. The shares are listed on the Nasdaq under the ticker symbol GSHTU. Gores Holdings I acquired Hostess Brands last year and completed an IPO in December for Hostess Brands Inc. (NASDAQ: TWNK).

Top 10 Medical Stocks To Buy For 2018: Staffing 360 Solutions, Inc.(STAF)

Advisors’ Opinion:

  • [By Bryan Murphy]

    The staffing industry – and the IT staffing industry in particular – is poised for tremendous growth in the foreseeable future, and that rising tide bodes very well for Staffing 360 Solutions Inc. (NASDAQ:STAF).

  • [By Matthew Briar]

    If there was any lingering doubt about Staffing 360 Solutions Inc (NASDAQ:STAF), it was wiped away today. The IT staffing firm’s second quarter numbers verify the long-standing growth trend is still well intact. Better still, even as the top line rises, expense-cuts supported by all the synergies of its recent acquisitions have allowed the bottom line to improve by even more.

    Even before today’s official Q2 announcement we knew that last quarter’s revenue would roll in at $47.1 million and gross profits would end up at $8.1 million. Those figures were up 14% and 8.4%, respectively. What we didn’t know about STAF until today is that the net loss shrank from $3.4 million a year earlier to only $1.5 million now. EBITDA of $1.4 million was about the same as the EBITDA of $1.3 million generated in the second fiscal quarter of the prior year.

    The progress march continues for Staffing 360 Solutions.

  • [By James E. Brumley]

    It’s almost time for the annual Staffing 360 Solutions Inc (NASDAQ:STAF) shareholder pow-wow. That is to say, the company’s annual shareholder meeting is scheduled for January 26th of the coming year, in New York City. Though nothing too dramatic is on the voting docket, a handful of items will be decided on by STAF owners.

    Staffing 360 Solutions is a fast-growing staffing firm. Its focal point is IT staffing. This small company is smartly and cost-effectively acquiring its way into a size and scale by converting a fragmented and less-effective and less profitable group of similar staffing agencies into a cohesive, more profitable singular unit.

    It’s paying off too – the proof has been in the rising revenue tally over the course of the past couple of years… a rise that’s been outpaced by the broad improvement of EBITDA and income (which is the point of a scale-up).

    The specific numbers: . All told, Staffing 360 Solutions generated $47.8 million worth of revenue last quarter, turned $8.5 million of it into a gross profit, and turned $1.8 million of that into an EBITDA profit. Those were, respectively, improvements of 33%, 34%, and 184% compared to the same quarter a year earlier. Net income improved too. The net loss of $1.3 million was 27% smaller than the net loss of $1.7 million booked in Q1 of fiscal 2016. Profitability – real profitability – is within reach. STAF simply has to stay on the trajectory it’s on. A couple more acquisitions and a little more organic growth could do the trick.

    Late next month, shareholders will have a chance to voice their thoughts on where the company should be going… metaphorically and literally. One of the matter being put to a vote is a change of domicile, from Nevada to Delaware; Delaware generally offers a more business-friendly set of operating and tax rules. Another more important matter to be voted on at the meeting is the authorization of more STAF shares, which have been used in lie

  • [By Peter Graham]

    Small cap staffing stock Staffing 360 Solutions Inc (NASDAQ: STAF), which is in the midst of a global buy-and-build strategy through the acquisition of domestic and international staffing organizations with operations in the US and UK, pre-announced its unaudited financial results for the fiscal second quarter ended November 30, 2016. Expected revenue rose 14% to$47 million and expected gross profit rose 8% to $8.1 million while for the first six months of the fiscal year, expected revenuerose 23% to$95 million and expected gross profit rose 20% to $16.6 million.

  • [By Matthew Briar]

    Staffing 360 Solutions Inc (NASDAQ:STAF) is on a roll. Just a couple of days after it pre-announced some impressive preliminary results for the most recently-completed quarter, the IT staffing agency told STAF shareholders today that $2.7 million worth of debt had essentially been refinanced. Now, no interest payments are due until October of this year, and no principal is due until October of next year. That may well be enough time for Staffing 360 Solutions to acquire more companies, beef up the top and bottom line, and pay the whole amount off before another refinancing or conversion to shares.

    Staffing 360 Solutions’ story is a compelling one. Seeing the growing need for information technology workers in an increasingly digital and increasingly networked world — and a severe lack of those qualified workers — three years ago the company began to capitalize on the supply/demand imbalance. Its mission was to aggregate, or “roll up” several smaller IT staffing companies into one big one, create some synergies and thus widen margins, and develop enough muscle to become THE dominant name in the niche.

    It’s working too. On Tuesday of this week, the company pre-announced its fiscal first quarter (ending in November) sales and gross profits. Revenue of $47 million and a gross profit of $8.1 million were up 14% and 8%, respectively, year-over-year, extending a long-term growth trend.

    What we haven’t heard yet — and won’t until the official Q1 filing is submitted later this month — is the company’s net income and EBITDA figures for the quarter. But, those numbers are improving too. EBITDA has been positive in each of the five prior quarters, and is expected to continue growing through last quarter. Net income is within sight of turning positive too. And, with its debt-interest payments now going away for at least nine months, net income will move towards turning positive at an even faster rate… through lower expenses, as well as greater fin

Top 10 Medical Stocks To Buy For 2018: U.S. Physical Therapy, Inc.(USPH)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares fell 0.73 percent. Meanwhile, top losers in the sector included U.S. Physical Therapy, Inc. (NYSE: USPH), down 7 percent, and Fluidigm Corporation (NASDAQ: FLDM), down 7 percent.

Top 10 Medical Stocks To Buy For 2018: Realogy Holdings Corp.(RLGY)

Advisors’ Opinion:

  • [By Chad Tracy]

    Investments in Claire's retail stores, Realogy Holdings (NYSE: RLGY), and Harrah's Entertainment all came under pressure as the global credit crisis hit. Apollo was forced to shut off cash interest payments to investors and to issue more debt.  

  • [By Lisa Abramowicz]

    Drugstore chain Rite Aid Corp. (RAD) and residential property firm Realogy Corp. (RLGY) are two of the 283 junk-rated borrowers identified in March 2009 by Moodys Investors Service as being at the highest risk of default that have since sold bonds.

  • [By Monica Wolfe]

    Realogy Holdings (RLGY)

    Paulsons third largest holding goes to Realogy Holdings. The guru holds on to 12,957,700 shares, representing 4.4% of his total portfolio and 8.87% of the companys shares outstanding.

Top 10 Medical Stocks To Buy For 2018: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.

    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.

  • [By Lisa Levin]

    Breaking news

    Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan.
    Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat.
    Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share.
    Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.

Top 10 Medical Stocks To Buy For 2018: Teck Resources Ltd(TCK)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Stephens (Equal-Weight) and Citi (Sell) both downgraded Atwood Oceanics (NYSE: ATW).

    Sell-Side's Most Noteworthy Calls
    Investec downgraded Anheuser-Busch (NYSE: BUD) to Hold.
    Deutsche Bank downgraded Freeport McMoRan (NYSE: FCX) to Hold.
    Goldman Sachs upgraded Microsoft (NASDAQ: MSFT) to Buy.
    Barclays upgraded Teck Resources (NYSE: TCK) to Overweight.
    BTIG started Adobe (NASDAQ: ADBE) at Neutral.
    Deal Talk

    U.S. oil refiner Tesoro (NYSE: TSO) said it would buy Western Refining (NYSE: WNR) for $4.1 billion to add refineries in Texas, New Mexico and Minnesota. The combined company will have refining capacity of over 1.1 million barrels per day. Tesoro has refineries in California, Washington, Alaska, Utah and North Dakota.

Top 10 Medical Stocks To Buy For 2018: iShares MSCI Emerging Markets (EEM)

Advisors’ Opinion:

  • [By Dan Caplinger]

    2017 has been a tumultuous year, with plenty going on in the political and financial realms. Yet the stock market has done quite well, and index funds that track popular stock benchmarks have given their investors solid returns. In particular, among the most popular exchange-traded funds, iShares MSCI Emerging Markets (NYSEMKT:EEM), PowerShares QQQ (NASDAQ:QQQ), and iShares Core MSCI EAFE (NYSEMKT:IEFA) have delivered some of the best returns.

  • [By WWW.GURUFOCUS.COM]

    For the details of RABOBANK NEDERLAND ‘s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=RABOBANK+NEDERLAND+

    These are the top 5 holdings of RABOBANK NEDERLAND Bank of America Corporation (BAC) – 250,000 shares, 100% of the total portfolio. New PositionBlackBerry Ltd (BBRY) – 0 shares, 0% of the total portfolio. Shares reduced by 10000%iShares MSCI Emerging Index Fund (EEM) – 0 shares, 0% of the total portfolio. Shares reduced by 10000%iShares MSCI Brazil Capped Index Fund (EWZ) – 0 shares, 0% of the total portfolio. Shares reduced by 10000%VanEck Vectors Gold Miners (GDX) – 0 shares, 0% of the total portfolio. Shares reduced by 10000%

  • [By Craig Jones]

    On CNBC's Trading Nation, Todd Gordon recommended a bearish options strategy in iShares MSCI Emerging Markets Indx (ETF) (NYSE: EEM). He said that the ETF is under pressure because of weak commodity prices and strong U.S. dollar. He explained that falling bond prices have caused a rally in the U.S. dollar.

  • [By Craig Jones]

    Speaking on Bloomberg Markets, Dan Deming of KKM Financial suggested a bullish options strategy in iShares MSCI Emerging Markets Indx (ETF) (NYSE: EEM).

Top 10 Medical Stocks To Buy For 2018: Nordstrom Inc.(JWN)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    There seems to be no cure for the rise of e-commerce, Cramer admitted to viewers, as a vicious downgrade of Nordstrom (JWN) last week sent shares reeling by more than 9%.

  • [By Chris Lange]

    Nordstrom, Inc. (NYSE: JWN) reported fiscal first-quarter financial results after markets closed Thursday. The company reported $0.43 in earnings per share (EPS) and $3.3 billion in revenue versus consensus estimates from Thomson Reuters that called for $0.27 in EPS and $3.34 billion in revenue. The same period from last year had $0.26 in EPS and $3.25 billion in revenue.

  • [By Dan Caplinger]

    The retail industry has gone through tough times lately, and things have been especially difficult for high-end retailers like Nordstrom (NYSE:JWN). As shoppers become more comfortable with online shopping, department stores with substantial brick-and-mortar assets have had to adapt to changes in consumer behavior and meet them on their own terms, and that’s been a difficult proposition for a company that prides itself on one-on-one customer service in the store setting.

Top 10 Clean Energy Stocks To Buy Right Now

Japanese equities kicked off the new year sharply higher on Wednesday, leading the regions gains amid a robust outlook for the U.S. economy, coupled with expectations of continued yen weakness.

The Nikkei Stock Average
NIK, +2.51%
was up 2.2%, with the market reopening after a four-day holiday weekend, helped by gains in financial and export-oriented stocks.

Top 10 Clean Energy Stocks To Buy Right Now: Sempra Energy(SRE)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, utilities shares fell by 0.93 percent. Meanwhile, top losers in the sector included Sempra Energy (NYSE: SRE), down 3 percent, and CenterPoint Energy, Inc. (NYSE: CNP), down 3 percent.

  • [By Shanthi Rexaline]

    Giving six reasons for Sempra Energy (NYSE: SRE)’s above-peer-average growth, Argus said it is reiterating its Hold rating on the shares of the company, while it is also maintaining its long-term Buy rating.

  • [By Lisa Levin]

    Sempra Energy (NYSE: SRE) announced plans to acquire Oncor for $9.45 billion in cash.

    Sempra Energy projects the deal to complete in the first half of 2018.

  • [By David Dittman]

    PG&E Corp (NYSE: PCG), Edison International (NYSE: EIX) and Sempra Energy (NYSE: SRE) are the parent entities of California’s investor-owned utilities.

Top 10 Clean Energy Stocks To Buy Right Now: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.

    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

  • [By Lisa Levin]

    Breaking news

    Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan.
    Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat.
    Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share.
    Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.

Top 10 Clean Energy Stocks To Buy Right Now: Oil States International Inc.(OIS)

Advisors’ Opinion:

  • [By Michael J. Carr]

    Einhorn selects investments with a traditional value approach, although he may not be as patient as a typical value investor. Einhorn took Apple (Nasdaq: AAPL) to court in an effort to force the company to return cash to shareholders, and more recently challenged Oil States International (NYSE: OIS) to unlock shareholder value.

  • [By Wayne Duggan]

    Instead, Genargo prefers oil services stocks with the most exposure to the U.S market. Loop names Halliburton Company (NYSE: HAL) as its top large-cap stock pick and Oil States International, Inc. (NYSE: OIS), Newpark Resources Inc (NYSE: NR) and Superior Energy Services, Inc. (NYSE: SPN) as its top small- and mid-cap stocks.

Top 10 Clean Energy Stocks To Buy Right Now: CAE Inc(CAE)

Advisors’ Opinion:

  • [By Paul Ausick]

    Five teams are expected to compete for the contract: Boeing Co. (NYSE: BA) has joined with Saab to offer a clean-sheet design; Northrop Grumman Corp. (NYSE: NOC) has teamed up with BAE Systems and L-3 Communications Holdings Inc. (NYSE: LLL) on another clean-sheet design; Lockheed Martin Corp. (NYSE: LMT) and Korea Aerospace Industries (KAI) are going with a modified KAI T-50; Raytheon Corp. (NYSE: RTN) has joined with Italy’s Leonardo and Canada’s CAE Inc. (NYSE: CAE) on a version of Leonardo’s M-346 trainer that it calls the T-100; and privately held Sierra Nevada has partnered with Turkish Aerospace Industries (TAI) on another clean-sheet design.

Top 10 Clean Energy Stocks To Buy Right Now: Broadcom Corporation(BRCM)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Susquehanna reported on Tuesday that it has raised its rating on Broadcom Corporation (BRCM).

    The firm has upgraded BRCM from “Neutral” to “Positive,” and has lifted the company’s price target from $33 to $35. This price target suggests a 23% upside from the stock’s current price of $26.91.

    Analyst Chris Caso commented: “Our downgrade of BRCM in May was predicated on already high Street expectations on handsets and no notable improvement in networking to drive upside. We think expectations and the stock price have now been sufficiently reset ahead of what we expect to be catalysts in 2014 including the iPhone 6 product cycle, potential improvement in networking and the impact from the recent Renesas acquisition. In addition, after several years of overspending on their handset initiatives, we think we are now closer to the point where the company either captures a return on that investment or is forced to moderate spending either of which benefit profitability. We see the upcoming December analyst meeting as a potential intermediate catalyst.”

    Broadcom shares were up 38 cents, or 1.41%, during pre-market trading Tuesday. The stock is down 19% YTD.

Top 10 Clean Energy Stocks To Buy Right Now: Frontline Ltd.(FRO)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    Frontline Ltd. (NYSE: FRO) is projected to post a loss in the second quarter, translating to a zero dividend, Credit Suisse said in a Tuesday note. Notwithstanding the negative opinion, the shares of the company were up in reaction to the possibility of a deal being struck.

  • [By Rich Smith]

    So what is it that’s supporting DHT’s stock price in the face of sliding shipping rates for crude oil, retreating revenue, and plunging profits? Well, for one thing, rival tanker companyFrontline (NYSE:FRO) made an unsolicited bid to acquire DHT last week, offering to pay $475 million for the company. (DHT is currently valued at $460 million.)

  • [By Lisa Levin]

    Wednesday afternoon, the energy shares surged 1.23 percent. Meanwhile, top gainers in the sector included Frontline Ltd. (NYSE: FRO), up 5 percent, and JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO), up 6 percent.

Top 10 Clean Energy Stocks To Buy Right Now: Myers Industries, Inc.(MYE)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, basic materials shares fell 0.63 percent. Meanwhile, top losers in the sector included Myers Industries, Inc. (NYSE: MYE), down 7 percent, and CF Industries Holdings, Inc. (NYSE: CF) down 6 percent.

Top 10 Clean Energy Stocks To Buy Right Now: TOP Ships Inc.(TOPS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares rose 47.1 percent to $3.22 in pre-market trading after jumping 54.23 percent on Wednesday.
    Digital Power Corporation (NYSE: DPW) rose 27.6 percent to $0.800 in pre-market trading after gaining 9.79 percent on Wednesday.
    Social Reality Inc (NASDAQ: SRAX) shares rose 23.1 percent to $7.16 in the pre-market trading session after surging 37.59 percent on Wednesday.
    China Auto Logistics Inc (NASDAQ: CALA) rose 16.9 percent to $4.15 in pre-market trading after gaining 4.11 percent on Wednesday.
    Riot Blockchain Inc (NASDAQ: RIOT) rose 15.1 percent to $18.40 in pre-market trading after climbing 42.01 percent on Wednesday.
    Seven Stars Cloud Group Inc (NASDAQ: SSC) rose 14.5 percent to $2.85 in the pre-market trading session after gaining 0.40 percent on Wednesday.
    Affimed NV (NASDAQ: AFMD) shares rose 14.3 percent to $2.40 in pre-market trading after gaining 4.88 percent on Wednesday.
    Corecivic Inc (NYSE: CXW) rose 10.2 percent to $25.56 in pre-market trading after climbing 0.65 percent on Wednesday.
    LM Funding America, Inc. (NASDAQ: LMFA) rose 9.6 percent to $3.30 in pre-market trading after surging 34.98 percent on Wednesday.
    U.S. Global Investors, Inc. (NASDAQ: GROW) rose 7.2 percent to $3.30 in pre-market trading after dropping 8.06 percent on Wednesday.
    Xunlei Ltd (NASDAQ: XNET) rose 6.8 percent to $25.61 in pre-market trading after climbing 11.74 percent on Wednesday.
    Net 1 UEPS Technologies Inc (NASDAQ: UEPS) shares rose 5.9 percent to $13.00 in pre-market trading after gaining 21.34 percent on Wednesday.
    Addus Homecare Corporation (NASDAQ: ADUS) rose 5.5 percent to $35.60 in pre-market trading after gaining 3.69 percent on Wednesday.
    TOP SHIPS Inc (NASDAQ: TOPS) rose 5.2 percent to $0.528 in pre-market trading after falling 10.36 percent on Wednesday.
    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) rose 4.7 percent to $14.11 in pre-market trading. Teva Pharma
  • [By Paul Ausick]

    Top Ships Inc. (NASDAQ: TOPS) posted a new 52-week low of $0.49 on Tuesday, down about 0.6% compared with Monday’s closing price of $0.52. The stock’s 52-week high is $8.40. Volume was about 4 times the daily average of around 2.8 million shares. The company had no specific news.

  • [By Lisa Levin] Related HTGM Mid-Afternoon Market Update: Dow Falls 50 Points; Micron Shares Jump Following Strong Earnings Report Mid-Day Market Update: ZAIS Group Gains Following Q4 Results; Xenon Pharmaceuticals Shares Decline HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN … (GuruFocus)
    Related Mid-Afternoon Market Update: Dow Falls 50 Points; Micron Shares Jump Following Strong Earnings Report Mid-Day Market Update: ZAIS Group Gains Following Q4 Results; Xenon Pharmaceuticals Shares Decline Zais Group reports Q4 results (Seeking Alpha)
    HTG Molecular Diagnostics Inc (NASDAQ: HTGM) shares climbed 204.1 percent to $11.95 after surging 83.64 percent on Thursday. HTG Molecular Diagnostics reported a Q4 loss of $0.76 per share on revenue of $1.5 million.
    ZAIS Group Holdings, Inc. (NASDAQ: ZAIS) shares surged 52.6 percent to $3.45. ZAIS Group reported Q4 earnings of $0.29 per share on revenue of $16.73 million.
    Global Brokerage Inc (NASDAQ: GLBR) shares jumped 24.3 percent to $2.30.
    Regulus Therapeutics Inc (NASDAQ: RGLS) shares surged 20 percent to $1.50. Regulus Therapeutics’ Chairman bought 500,000 shares at $1.22 per share.
    Rocket Fuel Inc (NASDAQ: FUEL) shares gained 15.6 percent to $5.19.
    Akoustis Technologies Inc (NASDAQ: AKTS) rose 13.3 percent to $10.75 as the company agreed to acquire wafer manufacturing facility for $2.75 million in cash.
    TOP SHIPS Inc (NASDAQ: TOPS) shares gained 12.6 percent to $1.25.
    Inventure Foods Inc (NASDAQ: SNAK) jumped 10.4 percent to $4.46 after the company announced the strategic sale of Fresh Frozen Foods for $23.7 million in cash.
    CymaBay Therapeutics Inc (NASDAQ: CBAY) surged 8.7 percent to $4.14. Cymabay Therapeutics reported a Q4 loss of $0.30 per share.
  • [By Paul Ausick]

    Top Ships Inc. (NASDAQ: TOPS) posted a new 52-week low of $0.51 on Friday, down more than 21% compared with Thursday’s closing price of $0.65. The stock’s 52-week high is $8.40. Volume was nearly double the daily average of around 2.3 million shares. The company had no specific news.

  • [By Lisa Levin] Related Chardan Analyst Suggests An AveXis-Ionis Pair Trade Why The Biogen-Ionis News Is A Boon For AveXis AveXis' (AVXS) CEO Sean Nolan on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related CLBS Earnings Scheduled For March 17, 2017 15 Biggest Mid-Day Gainers For Thursday Caladrius Biosciences beats by $0.07, beats on revenue (Seeking Alpha) Gainers
    Caladrius Biosciences Inc (NASDAQ: CLBS) shares rose 20.2 percent to $6.13 in pre-market trading after the company reported a narrower-than-expected quarterly loss.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 12.3 percent to $3.20 in pre-market trading after the company disclosed that it has licensed LNP delivery technology to Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for use in single messenger RNA product candidate.
    AveXis Inc (NASDAQ: AVXS) rose 12.2 percent to $81.66 in pre-market trading after the company reported topline data from Phase 1 trial of AVXS-101.
    TOP SHIPS Inc (NASDAQ: TOPS) shares rose 10.5 percent to $2.43 in pre-market trading after surging 109.52 percent on Thursday.
    ChipMOS TECHNOLOGIES INC. (NASDAQ: IMOS) rose 9.8 percent to $17.45 in pre-market trading after declining 0.44 percent on Thursday.
    Sino-Global Shipping America, Ltd. (NASDAQ: SINO) rose 8.3 percent to $3.38 in pre-market trading after climbing 23.81 percent on Thursday.
    Diana Containerships Inc (NASDAQ: DCIX) rose 7.6 percent to $2.99 in pre-market trading after surging 12.55 percent on Thursday.
    Steel Dynamics, Inc. (NASDAQ: STLD) rose 5.2 percent to $37.25 in pre-market trading. Steel Dynamics expects Q1 earnings of $0.77 to $0.81 per diluted share. The company also declared a quarterly cash dividend of $0.1550 per common share.
    Adobe Systems Incorporated (NASDAQ: ADBE)
  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli

Top 10 Clean Energy Stocks To Buy Right Now: Jewett-Cameron Trading Company(JCTCF)

Advisors’ Opinion:

  • [By Lisa Levin]

    Jewett-Cameron Trading Company Ltd (NASDAQ: JCTCF) shares shot up 11 percent to $13.35. Jewett-Cameron reported Q3 earnings of $0.53 per share on revenue of $16.7 million.

Top 10 Clean Energy Stocks To Buy Right Now: PDC Energy, Inc.(PDCE)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Goldman Sachs analyst Brian Singer and team contend that EOG Resources (EOG), Diamondback Energy (FANG), PDC Energy (PDCE), Pioneer Natural Resources (PXD), and RSP Permian (RSPP) can benefit from greater productivity. They explain:

  • [By Ben Levisohn]

    Names which screen well on a combination of attractive valuation and equitized capital structure, include Outperform rated Apache, Anadarko Petroleum,Gulfport Energy as well as Market Perform rated QEP Resources (QEP) and PDC Energy (PDCE).

usa stock market

America is a nation of borrowers, and while racking up debt can be dangerous at any age, it’s especially hazardous for those heading into retirement.

Because most seniors are behind on savings to begin with, carrying debt into retirement will only strain their already limited budget. Yet a growing number of households are kicking off their golden years with piles of debt — in fact, 20% of borrowers actually expect to die in debt.

According to the Consumer Financial Protection Bureau, 30% of homeowners aged 65 and older still carry mortgage debt — granted, housing debt is technically the “good” kind to have. However, credit card debt can be particularly detrimental for seniors, and ValuePenguin reports that Americans 65 and older have average credit card balances of $6,351.

While the picture of retiree debt isn’t pretty, the good news is that you can take steps to rid yourself of your nagging obligations in time for retirement. Here’s how.

1. Build up a chunk of emergency savings

usa stock market: RetailMeNot, Inc.(SALE)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, RetailMeNot (NASDAQ:SALE) and SUPERVALU (NYSE:SVU) attracted heavy investor interest following merger and acquisition news.

  • [By Lisa Levin]

    Shares of RetailMeNot Inc (NASDAQ: SALE) got a boost, shooting up 12 percent to $8.42. RetailMeNot announced after Thursday’s close it has entered into an agreement to acquire GiftCard Zen, a secondary marketplace for gift cards. The company reported preliminary Q1 revenue of $54 million to $54.5 million and FY16 revenue of $228 million to $241 million.

usa stock market: LightInTheBox Holding Co., Ltd.(LITB)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggested small cap China based online retailstockLightinthebox Holding Co (NYSE: LITB) as a long/buy trade:

  • [By Peter Graham]

    Small cap China based online retailstockLightinthebox Holding Co (NYSE: LITB) reportedQ1 2017 earnings as net revenues increased 8.0% to $72.7 million (above the high end of the Company’s guidance of $72.0 million). Net revenues from product sales were $64.8 million versus$61.9 million and net revenues from service and others were $7.9 million versus $5.4 million in the same quarter of 2016. As a percentage of net revenues, service and others accounted for 10.9% during the first quarter of 2017. Total orders of product sales were 1.6 million for the first quarter of 2017 versus1.7 million in the same quarter of 2016 while the total number of product sales customers was 1.2 million versus 1.4 million.

usa stock market: Fidelity Southern Corporation(LION)

Advisors’ Opinion:

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on Monday.

    AptarGroup, Inc. (NYSE: ATR) – $0.3200 dividend, 1.6780 percent yield. AptarGroup reported weaker-than-expected Q3 results on Thursday.
    Fidelity Southern Corporation (NASDAQ: LION) – $0.1200 dividend, 2.6359 percent yield. The company, based in Atlanta, Georgia, provides financial products and services for customers.
    Apple Hospitality REIT Inc (NYSE: APLE) – $0.1000 dividend, 6.5826 percent yield. Apple Hospitality REIT, based in Richmond, Virginia, operates as a subsidiary of Apple REIT Companies.
    Targa Resources Corp (NYSE: TRGP) – $0.9100 dividend, 7.7299 percent yield. The Houston, Texas-based company provides midstream natura

usa stock market: Pound/Rand(PX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    The last twelve months haven’t been kind to Praxair (PX) and Air Products & Chemicals (APD), but UBS analyst John Roberts and team argue that’s about to change, as they upgrade their shares to Buy from Neutral arguing that their earnings can withstand a slowing global economy:

    In our view, the two stocks are more alike than different. NTM P/Es are within ~0.5 pts of each other. Both stocks have declined ~20% from their historical highs the largest corrections in 20+ years aside from the financial crisis…

    Industrial gas stocks have normally grown through changes in FX, oil & China demand within normal historical ranges. And investor concerns around China forAir Products & Chemicals may still prove much bigger than reality. Nevertheless, the combination of FX & oil sector impacts on Praxair, and FX & China issues for Air Products & Chemicals, have been much larger than previously seen. With oil already down, the dollar already appreciated, & China concerns already heightened we believe forward basis would appear to carry only normal risks (& lower if FX & oil are mean-reverting, which some theories support).

    Normal high single digit EPS growth projected for both in 2017 vs 2016: Four large firms serve 70%+ of the global merchant gas market, and price normally contributes ~2% to growth. Customer older captive units being outsourced contributes another 2%. Secular drivers for oxygen include energy savings (i.e. O2 burns more efficiently than air), life sciences (healthcare & microbial processes) nitrogen secular drivers include increasing purity requirements (food freezing & semiconductors). Topline growth ~2x global GDP more normal, with EPS growth ~2x sales growth due to high fixed costs (key variable costs are inexpensive air & power).

    Financial crisis demand drop was only a few %, in line with global GDP drop Most chemicals volumes dropped 10%+ (some 40%

usa stock market: Fitbit, Inc.(FIT)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap fitnessdevice stock and wearables stockFitbit Inc (NYSE: FIT) started off as a high flyer after its 2015 IPO, but those highflying days have largely ended as you can see from its long term performance chart:

  • [By Peter Graham]

    The Q4 2016 earnings report forsmall cap fitnessdevice stockFitbit Inc (NYSE: FIT) is scheduled for after the market closes onWednesday (February 22nd). Competition in the fitness device and wearables market has made Fitbit Inc theseventh most shorted stock on the NYSE with elevated short interest of 38.92% according to Highshortinterest.com. At the end of January, Fitbit Incs CEOwarned that:

  • [By Leo Sun]

    Under Armour (NYSE:UA) (NYSE:UAA), Fitbit (NYSE:FIT), and GoPro (NASDAQ:GPRO) were all terrible stocks to own over the past year. Under Armour and Fitbit were both cut in half, and GoPro plummeted nearly 40%.

  • [By Tracey Ryniec]

    Fitbit is the latest tech gadget sensation. It has 22% of the wearables market and it looks like this holiday season could be huge for the company. Fitness and wellness are a big market globally which Fitbit is only beginning to tap. 

  • [By Dustin Blitchok]

    The NBA authorized jersey sponsorships last year, and Flagstar joins companies such as Goodyear Tire & Rubber Co (NASDAQ: GT), Fitbit Inc (NYSE: FIT), eBay Inc (NASDAQ: EBAY) and General Electric Company (NYSE: GE) in sponsoring a team’s jersey.

usa stock market: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By Lisa Levin]

    Breaking news

    Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan.
    Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat.
    Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share.
    Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.

    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.